Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China - Top-Institutions - MDSpire

Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China

  • By

  • Wanyan Xiang

  • Jiarong Lu

  • Siqi Zhang

  • Wenjun Zheng

  • Qiuju Li

  • July 6, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    First Affiliated Hospital of Guangxi Medical University
    First Affiliated Hospital of Guangxi Medical University

    Nanning, Guangxi

    Key Differentiators

    • Rheumatology

Original Source(s)

Efficacy and safety of upadacitinib in treating immune drift: a single-center, prospective study in China

  • by Wanyan Xiang, Jiarong Lu, Siqi Zhang, Wenjun Zheng, Qiuju Li

  • July 6, 2026

Related Content

Case Report: Paradoxical psoriasis under TNF-α blockade may represent generalized abscessing staphyloderma – GASD syndrome by TNF antagonists

FDA Expands Guselkumab Label in PsA

Phase 3b APEX findings support the addition of structural joint damage inhibition data to the prescribing information.

Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy